CRS

Four privately funded advanced reactors just went critical for the first time in 50+ years, with one company targeting $1B raise and million-sq-ft manufacturing expansion. The obvious trade (uranium, reactor developers) is crowded. The real edge is long US mid-cap specialty industrial manufacturers supplying nuclear-grade materials and precision components — a bottleneck the market is systematically underpricing.